19 results on '"Liu, Lawrence Yu-Min"'
Search Results
2. Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis.
- Author
-
Kuo, Hsiao-Huai, Wang, Kuang-Te, Chen, Hsin-Hao, Lai, Zih-Yin, Lin, Po-Lin, Chuang, Yung-Jen, and Liu, Lawrence Yu-Min
- Subjects
- *
TYPE 2 diabetes , *SODIUM-glucose cotransporter 2 inhibitors , *HEART failure patients , *DIABETIC acidosis - Abstract
Background: Cancer patients with diabetes are at increased risk for cardiovascular diseases due to common risk factors and well-documented drug-associated cardiotoxicity. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown cardiovascular benefits in patients with diabetes, but their effects on cancer patients remain unclear. This study aimed to evaluate the cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with concomitant diabetes and cancer. Methods: We conducted a systematic review and meta-analysis of cohort studies comparing cardiovascular outcomes between cancer patients with diabetes receiving SGLT2 inhibitors and those not receiving SGLT2 inhibitors. PubMed, Embase, and the Cochrane Library were searched from inception to February 29, 2024. The primary outcome was all-cause mortality, and the secondary outcomes were heart failure hospitalization, and adverse events. Random-effect models were used to calculate pooled risk ratios (RR) with 95% confidence intervals (CI). Subgroup and sensitivity analyses were conducted to identify potential sources of heterogeneity and explore the effect of SGLT2 inhibitors on mitigating cardiotoxicity. Results: Nine cohort studies involving 82,654 patients were included. SGLT2 inhibitor use was associated with a significantly lower risk of all-cause mortality (RR 0.46, 95% CI 0.31–0.68, P < 0.0001; I2 = 98%) and heart failure hospitalization (RR 0.49, 95% CI 0.30–0.81, P = 0.006; I2 = 21%) compared to non-use. The mortality benefit remained significant in patients receiving anthracycline chemotherapy (RR 0.50, 95% CI 0.28–0.89, P = 0.02; I2 = 71%). SGLT2 inhibitor use was also associated with a lower risk of sepsis (RR 0.32, 95% CI 0.23–0.44, P < 0.00001; I2 = 0%) and no increased risk of diabetic ketoacidosis (RR 0.66, 95% CI 0.20–2.16, P = 0.49; I2 = 0%). Conclusions: SGLT2 inhibitor therapy is associated with lower risks of all-cause mortality and heart failure hospitalization in patients with concomitant diabetes and cancer. These findings suggest that SGLT2 inhibitors may offer cardiovascular benefits in this high-risk population. Randomized controlled trials are needed to validate these findings and evaluate the safety and efficacy of SGLT2 inhibitors in specific cancer types and treatment regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells.
- Author
-
Shyu, Yueh-Ming, Liu, Lawrence Yu-Min, and Chuang, Yung-Jen
- Subjects
- *
HISTONE deacetylase inhibitors , *VALPROIC acid , *DOUBLE-strand DNA breaks , *ANTINEOPLASTIC agents , *CHEMOSENSITIZERS , *BRAF genes , *HISTONE deacetylase , *DACARBAZINE - Abstract
Melanoma is the most lethal form of skin cancer, which is intrinsically resistant to conventional chemotherapy. Combination therapy has been developed to overcome this challenge and show synergistic anticancer effects on melanoma. Notably, the histone deacetylase inhibitor, valproic acid (VPA), has been indicated as a potential sensitizer of chemotherapy drugs on various metastatic cancers, including advanced melanoma. In this study, we explored whether VPA could serve as an effective sensitizer of chemotherapy drug etoposide (ETO) on B16-F10 and SK-MEL-2-Luc melanoma cell lines in response to drug-induced DNA damages. Our results demonstrated that the VPA-ETO simultaneous combined treatment and ETO pretreated sequential combined treatment generated higher inhibitory effectivities than the individual treatment of each drug. We found the VPA-ETO simultaneous combined treatment contributed to the synergistic inhibitory effect by the augmented DNA double-strand breaks, accompanied by a compromised homologous recombination activity. In comparison, the ETO pretreated sequential combined treatment led to synergistic inhibitory effect via enhanced apoptosis. Surprisingly, the enhanced homologous recombination activity and G2/M phase arrest resulted in the antagonistic effect in both cells under VPA pretreated sequential combined treatment. In summary, our findings suggested that sequential order and effective dose of drug administration in VPA-ETO combination therapy could induce different cellular responses in melanoma cells. Such understanding might help potentiate the effectiveness of melanoma treatment and highlight the importance of sequential order and effective dose in combination therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Diverse Adiposity and Atrio-Ventricular Dysfunction across Obesity Phenotypes: Implication of Epicardial Fat Analysis.
- Author
-
Lai, Yau-Huei, Liu, Lawrence Yu-min, Sung, Kuo-Tzu, Tsai, Jui-Peng, Huang, Wen-Hung, Yun, Chun-Ho, Lin, Jiun-Lu, Chen, Ying-Ju, Su, Cheng-Huang, Hung, Ta-Chuan, Hung, Chung-Lieh, Kuo, Jen-Yuan, and Cena, Hellas
- Subjects
- *
FAT analysis , *CARDIOVASCULAR diseases , *ATRIAL fibrillation , *PHENOTYPES , *BODY mass index , *OBESITY - Abstract
Obesity has been conceptualized as a highly heterogeneous condition. We aim to investigate chamber-specific effects of obesity on the heart and relevant outcomes. A total of 2944 symptom-free individuals (age: 47.5 ± 10.0 years), free of known cardiovascular diseases were classified into four categories based on body mass index (BMI) (as normal-weight (NW) vs. overweight/obese (O)) and metabolic status (metabolically-healthy (MH) vs. unhealthy (MU)). Epicardial adipose thickness (EAT) using echocardiography method. Speckle-tracking based atrio-ventricular (LA/LV) deformations including global longitudinal strain (GLS) and peak atrial longitudinal strain (PALS) were also analyzed. MUNW had higher cardiometabolic risks and more impaired diastolic and GLS/PALS than MHNW phenotype. Both MHO and MUO phenotypes exhibited worst atrial functions. Greater EAT was independently associated with worse GLS and PALS after correcting for various anthropometrics, LV mass and LA volume, respectively, with unfavorable LA effects from EAT being more pronounced in the NW phenotypes (both p interactions < 0.05). During a median follow-up period of 5.3 years, BMI/EAT improved the reclassification for atrial fibrillation (AF) incidence (p for net reclassification improvement < 0.05) mainly in the NW phenotypes (p interaction < 0.001). Categorization of clinical obesity phenotypes based on excessive visceral adiposity likely provides increment prognostic impacts on atrial dysfunction, particularly in non-obese phenotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. TCTAP A-079 True Effect of Catheter-based Renal Denervation Across a Broad Spectrum of Patients: A Systematic Review and Meta-analysis.
- Author
-
Liu, Lawrence Yu-min, Lin, Po-Lin, Liao, Feng-Ching, Chiou, Wei-Ru, Lin, Shu-I., and Lee, Ying-Hsiang
- Subjects
- *
META-analysis , *DENERVATION , *ESSENTIAL hypertension - Published
- 2019
- Full Text
- View/download PDF
6. Aortic Root Remodeling as an Indicator for Diastolic Dysfunction and Normative Ranges in Asians: Comparison and Validation with Multidetector Computed Tomography.
- Author
-
Liu, Lawrence Yu-min, Yun, Chun-Ho, Kuo, Jen-Yuan, Lai, Yau-Huei, Sung, Kuo-Tzu, Yuan, Po-Jung, Tsai, Jui-Peng, Huang, Wen-Hung, Lin, Yueh-Hung, Hung, Ta-Chuan, Chen, Ying-Ju, Su, Cheng-Huang, Tsai, Cheng-Ting, Yeh, Hung-I, and Hung, Chung-Lieh
- Subjects
- *
MULTIDETECTOR computed tomography , *ASIANS , *SINUS of valsalva , *COMPUTED tomography , *HYPERTENSION - Abstract
Background: The aortic root diameter (AoD) has been shown to be a marker of cardiovascular risk and heart failure (HF). Data regarding the normal reference ranges in Asians and their correlates with diastolic dysfunction using contemporary guidelines remain largely unexplored. Methods: Among 5343 consecutive population-based asymptomatic Asians with echocardiography evaluations for aortic root diameter (without/with indexing, presented as AoD/AoDi) were related to cardiac structure/function and N-terminal pro-brain B-type natriuretic peptide (Nt-ProBNP), with 245 participants compared with multidetector computed tomography (MDCT)-based aortic root geometry. Results: Advanced age, hypertension, higher diastolic blood pressure, and lower body fat all contributed to greater AoD/AoDi. The highest correlation between echo-based aortic diameter and the MDCT-derived measures was found at the level of the aortic sinuses of Valsalva (r = 0.80, p < 0.001). Age- and sex-stratified normative ranges of AoD/AoDi were provided in 3646 healthy participants. Multivariate linear regressions showed that AoDi was associated with a higher NT-proBNP, more unfavorable left ventricular (LV) remodeling, worsened LV systolic annular velocity (TDI-s′), a higher probability of presenting with LV hypertrophy, and abnormal LV diastolic indices except tricuspid regurgitation velocity by contemporary diastolic dysfunction (DD) criteria (all p < 0.05). AoDi superimposed on key clinical variables significantly expanded C-statistic from 0.71 to 0.84 (p for ∆AUROC: < 0.001). These associations were broadly weaker for AoD. Conclusion: In our large asymptomatic Asian population, echocardiography-defined aortic root dilation was associated with aging and hypertension and were correlated modestly with computed tomography measures. A larger indexed aortic diameter appeared to be a useful indicator in identifying baseline abnormal diastolic dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus.
- Author
-
Kuo, Hsiao-Huai, Lai, Yau-Huei, Lin, Po-Lin, Chen, Hsin-Hao, Hung, Chung-Lieh, Liu, Lawrence Yu-Min, and Yeh, Chih-Kuang
- Subjects
- *
TYPE 2 diabetes , *GLOBAL longitudinal strain , *SPECKLE tracking echocardiography , *STROKE volume (Cardiac output) , *HEMODYNAMICS , *MYOCARDIAL reperfusion , *DIASTOLE (Cardiac cycle) - Abstract
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors have demonstrated to reduce cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) in large trials independent of glycemic control. The mechanisms of this cardioprotective property remain uncertain. Evidence suggests positive hemodynamic changes and favorable cardiac remodeling contributing to the clinical outcomes but results were conflicting. We aim to investigate the potential impact on hemodynamic parameters, cardiac structure and functions. This prospective observational study included T2DM patients receiving canagliflozin 100 mg per day in addition to their antidiabetic treatment. We analyzed hemodynamic parameters assessed by echocardiographic measurements and impedance cardiography (ICG) to evaluate systolic and diastolic functions from baseline to 24 weeks after treatment. A total of 47 patients (25 males and 22 females) averaging 64.6 ± 10.9 years had a significant reduction in HbA1c, body weight, and systolic blood pressure. Hematocrit increased significantly, while NT-proBNP remained unchanged. E/e′, left atrium (LA) volume, and LA stiffness were reduced, while left ventricle (LV) global longitudinal strain (GLS) and LA strain rates increased at 24 weeks by conventional and speckle tracking echocardiography. LV mass and ejection fraction showed no differences. ICG suggested significant improvement in hemodynamic parameters with increased stroke volume index and cardiac output index and decreased systemic vascular resistance index at 12 and 24 weeks. Canagliflozin improved hemodynamic parameters and had a favorable impact on LA and LV reverse remodeling. These changes may explain the beneficial effect on cardiovascular outcomes in large clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. TCTAP A-131 Impact of Sex Differences on Fractional Flow Reserve Is Influenced by Lesion Location.
- Author
-
Liu, Lawrence Yu-min, Lin, Po-Lin, and Wu, Hsu-Ping
- Subjects
- *
PERCUTANEOUS coronary intervention , *CORONARY heart disease treatment , *DISEASES in women , *SCIENTIFIC observation ,SEX differences (Biology) - Published
- 2016
- Full Text
- View/download PDF
9. Early detection of myocardial ischemia in resting ECG: analysis by HHT.
- Author
-
Wang, Chun-Lin, Wei, Chiu-Chi, Tsai, Cheng-Ting, Lee, Ying-Hsiang, Liu, Lawrence Yu-Min, Chen, Kang-Ying, Lin, Yu-Jen, and Lin, Po-Lin
- Subjects
- *
MYOCARDIAL ischemia , *ELECTROCARDIOGRAPHY , *ANGINA pectoris , *HILBERT-Huang transform , *STENOSIS , *EXERCISE tests - Abstract
Background: Exercise electrocardiography (ECG) is a noninvasive test aiming at producing ischemic changes. However, resting ECG cannot be adopted in diagnosing myocardial ischemia till ST-segment depressions. Therefore, this study aimed to detect myocardial energy defects in resting ECG using the Hilbert–Huang transformation (HHT) in patients with angina pectoris. Methods: Electrocardiographic recordings of positive exercise ECG by performing coronary imaging test (n = 26) and negative exercise ECG (n = 47) were collected. Based on the coronary stenoses severity, patients were divided into three categories: normal, < 50%, and ≥ 50%. During the resting phase of the exercise ECG, all 10-s ECG signals are decomposed by HHT. The RT intensity index, composed of the power spectral density of the P, QRS, and T components, is used to estimate the myocardial energy defect. Results: After analyzing the resting ECG using HHT, the RT intensity index was significantly higher in patients with positive exercise ECG (27.96%) than in those with negative exercise ECG (22.30%) (p < 0.001). In patients with positive exercise ECG, the RT intensity index was gradually increasing with the severity of coronary stenoses: 25.25% (normal, n = 4), 27.14% (stenoses < 50%, n = 14), and 30.75% (stenoses ≥ 50%, n = 8). The RT intensity index of different coronary stenoses was significantly higher in patients with negative exercise ECG, except for the normal coronary imaging test. Conclusions: Patients with coronary stenoses had a higher RT index at the resting stage of exercise ECG. Resting ECG analyzed using HHT could be a method for the early detection of myocardial ischemia. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. The autonomic balance of heart rhythm complexity after renal artery denervation: insight from entropy of entropy and average entropy analysis.
- Author
-
Lin, Po-Lin, Lin, Ping-Yen, Huang, Han-Ping, Vaezi, Hamideh, Liu, Lawrence Yu-Min, Lee, Ying-Hsiang, Huang, Chun-Che, Yang, Ten-Fang, Hsu, Long, and Hsu, Chang Francis
- Subjects
- *
RENAL artery , *HEART beat , *AMBULATORY blood pressure monitoring , *DENERVATION , *ENTROPY , *BLOOD pressure - Abstract
Background: The current method to evaluate the autonomic balance after renal denervation (RDN) relies on heart rate variability (HRV). However, parameters of HRV were not always predictive of response to RDN. Therefore, the complexity and disorder of heart rhythm, measured by entropy of entropy (EoE) and average entropy (AE), have been used to analyze autonomic dysfunction. This study evaluated the dynamic changes in autonomic status after RDN via EoE and AE analysis.Methods: Five patients were prospectively enrolled in the Global SYMPLICITY Registry from 2020 to 2021. 24-h Holter and ambulatory blood pressure monitoring (ABPM) was performed at baseline and 3 months after RDN procedures. The autonomic status was analyzed using the entropy-based AE and EoE analysis and the conventional HRV-based low frequency (LF), high frequency (HF), and LF/HF.Results: After RDN, the ABPM of all patients showed a significant reduction in blood pressure (BP) and heart rate. Only AE and HF values of all patients had consistent changes after RDN (p < 0.05). The spearman rank-order correlation coefficient of AE vs. HF was 0.86, but AE had a lower coefficient of variation than HF.Conclusions: Monitoring the AE and EoE analysis could be an alternative to interpreting autonomic status. In addition, a relative change of autonomic tone, especially an increasing parasympathetic activity, could restore autonomic balance after RDN. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. Rhythm control without catheter ablation may have benefits beyond stroke prevention in rivaroxaban-treated non-permanent atrial fibrillation.
- Author
-
Chiou, Wei-Ru, Lin, Po-Lin, Huang, Chun-Che, Chuang, Jen-Yu, Liu, Lawrence Yu-Min, Su, Min-I, Liao, Feng-Ching, Kuo, Jen-Yuan, Tsai, Cheng-Ting, Wu, Yih-Jer, Wang, Kuang-Te, and Lee, Ying-Hsiang
- Subjects
- *
CATHETER ablation , *MAJOR adverse cardiovascular events , *PROPENSITY score matching , *CONGESTIVE heart failure , *STATISTICAL matching , *ATRIAL fibrillation - Abstract
The current treatment paradigm for atrial fibrillation (AF) prioritizes rate control over rhythm control; however, rhythm control has shown benefits over other AF strategies. This study compares the outcomes of rivaroxaban with and without concomitant antiarrhythmic drugs (AADs), using propensity score matching to correct for statistical effects of baseline discrepancies. This multi-center retrospective study included 1,477 patients with non-permanent AF who took rivaroxaban for at least one month between 2011 and 2016 and had not received catheter ablation. Concomitant AAD use was compared against clinical outcome endpoints for effectiveness, safety, and major adverse cardiac events (MACE). Associations with concomitant AAD use were evaluated using multivariate Cox proportional hazard analyses. Patients were divided into two matched groups: rivaroxaban alone (n = 739) and with concomitant AADs (n = 738). The cumulative incidences of safety (p = 0.308), effectiveness (p = 0.583), and MACE (p = 0.754) were similar between the two groups, and multivariate analysis showed no significant differences. The new thromboembolism and all-cause death rates were higher in rivaroxaban alone (2.7% vs 0.8%, p = 0.005; and 10% vs. 6.9%, p = 0.032, respectively). The heart failure readmission rate was higher in the concomitant-AAD group (8.4% vs. 13.3%, p = 0.003). The concomitant use of rivaroxaban with AADs appears to be well-tolerated, with lower rates of thromboembolism and all-cause death, but is associated with more occurrences of congestive heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
- Author
-
Chiou, Wei-Ru, Huang, Chun-Che, Lin, Po-Lin, Chuang, Jen-Yu, Liu, Lawrence Yu-Min, Su, Min-I, Liao, Feng-Ching, Chen, Chun-Yen, Kuo, Jen-Yuan, Tsai, Cheng-Ting, Wu, Yih-Jer, and Lee, Ying-Hsiang
- Subjects
- *
THROMBOEMBOLISM risk factors , *MYOCARDIAL depressants , *DRUG efficacy , *RESEARCH , *COMBINATION drug therapy , *MULTIVARIATE analysis , *ATRIAL fibrillation , *RETROSPECTIVE studies , *MEDICAL cooperation , *RIVAROXABAN , *RISK assessment , *COMPARATIVE studies , *DRUG interactions , *DRUG side effects , *PATIENT safety , *LONGITUDINAL method , *PROPORTIONAL hazards models - Abstract
Introduction: Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm. Current guidelines contraindicate concomitant use of rivaroxaban with the popular AAD dronedarone, despite little data demonstrating interactions with AADs. This study investigates the outcomes of concomitant rivaroxaban and AAD drug use in a real-world cohort. Methods: This retrospective study included 1777 non-permanent AF patients taking rivaroxaban for ≥ 1 month between 2011 and 2016 from a multicenter cohort in Taiwan, and compared concomitant AAD use against clinical outcome endpoints for safety, effectiveness, and major adverse cardiac events (MACE). Multivariate Cox proportional hazard analyses were used to evaluate the association between concomitant AAD use and outcomes. Results: Patients were divided into rivaroxaban alone (n = 1205) and with concomitant amiodarone (n = 177), dronedarone (n = 231), or propafenone (n = 164) groups. The proportion of patients using rivaroxaban 10 mg was highest in the concomitant dronedarone group: rivaroxaban alone, 53.6%; with amiodarone, 57.6%; with dronedarone, 77.1%; and with propafenone, 46.3% (p < 0.001). The cumulative incidences of safety (p = 0.892), effectiveness (p = 0.336), and MACE (p = 0.674) were similar between the four groups; however, there were significantly fewer new systemic thromboembolisms in the dronedarone group: rivaroxaban alone, 2.5%; with amiodarone, 0.6%; with dronedarone, 0%; and with propafenone, 1.2% (p = 0.029). The all-cause death rate was also lowest in the dronedarone group: rivaroxaban alone, 9.0%; with amiodarone, 9.6%; with dronedarone, 3.0%; and with propafenone: 6.1% (p = 0.013). After covariate adjustment, there were no differences in the safety, effectiveness, and MACE endpoints between patients receiving or not receiving AADs. Conclusion: Concomitant use of rivaroxaban with AADs appears to be well tolerated, warranting further investigation into the apparent benefits of a reduced dose of rivaroxaban combined with dronedarone. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta‐analysis.
- Author
-
Kuo, Hsiao‐Huai, Wang, Kuang‐Te, Lee, Ying‐Hsiang, Lin, Po‐Lin, Liu, Ming‐En, Lin, Chien‐Yu, and Liu, Lawrence Yu‐Min
- Subjects
- *
BLOOD pressure , *BLOOD sugar , *CARDIOVASCULAR diseases risk factors , *COMPARATIVE studies , *GLYCOSYLATED hemoglobin , *HEART beat , *PATIENT aftercare , *INFORMATION storage & retrieval systems , *MEDICAL databases , *MEDICAL information storage & retrieval systems , *LOW density lipoproteins , *MEDLINE , *META-analysis , *METABOLISM , *OBESITY , *ONLINE information services , *SEROTONIN antagonists , *TRIGLYCERIDES , *ANTIOBESITY agents , *SYSTEMATIC reviews , *BODY mass index , *TREATMENT effectiveness , *WAIST circumference , *PHARMACODYNAMICS - Abstract
What is known and objective: Lorcaserin is a selective serotonin 2c receptor agonist approved as an anti‐obesity agent. The additional cardiometabolic benefits associated with lorcaserin have not been conclusively established. The aim of the systematic review and meta‐analysis is to examine the effects of lorcaserin on blood pressure, heart rate and other metabolic parameters in overweight and obese patients from randomized controlled clinical trials (RCTs). Methods: A literature search was conducted on PubMed, EMBASE and Cochrane Central using the search terms 'lorcaserin' and 'randomized controlled trials' without language restrictions. RCTs with a follow‐up period of at least 24 weeks were included in the meta‐analysis. Results and discussion: Six studies with 9452 patients in the lorcaserin group and 9392 patients in the placebo group were included. Compared with placebo, lorcaserin not only reduced weight, BMI and waist circumference but also improved SBP, DBP, heart rate, LDL, triglycerides, fasting plasma glucose and HbA1c. Our findings suggest that lorcaserin has trivial though consistent and favourable effects on blood pressure, heart rate and metabolic syndrome. What is new and conclusion: Lorcaserin improved all cardiometabolic parameters modestly in addition to its weight loss effect in overweight and obese patients. More research is needed to determine its long‐term cardiovascular benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Relations between baseline burden, maximum duration, and relative reduction of atrial fibrillation: Insights from continuous monitoring in rhythm control.
- Author
-
Lin, Po‐Lin, Huang, Chun‐Che, Wu, Yih‐Jer, Su, Min‐I, Chiou, Wei‐Ru, Liu, Lawrence Yu‐Min, Liao, Feng‐Ching, Lai, Edward, Chen, Chun‐Yen, Kuo, Jen‐Yuan, and Lee, Ying‐Hsiang
- Subjects
- *
ATRIAL fibrillation treatment , *MYOCARDIAL depressants , *CARDIAC pacemakers , *MEDICAL cooperation , *MULTIVARIATE analysis , *PATIENT monitoring , *RESEARCH , *RETROSPECTIVE studies , *DISEASE duration , *THERAPEUTICS - Abstract
Introduction: Cardiac implantable electronic devices (CIEDs) can measure atrial fibrillation (AF) early; however, the timing for administering antiarrhythmic drugs (AADs) to suppress AF remains unclear. This study aimed to investigate the association between baseline values and changes after AAD in terms of relative reduction of AF burden (RRAB) and maximum AF duration (RRMD). Methods: This multicenter retrospective study screened all patients with nonpermanent AF who had dual‐chamber pacemakers and only enrolled those receiving a naive AAD between September 2009 and December 2014. AF burden and maximum duration were calculated using CIED at 0 and 3 to 6 months after starting rhythm control. All the enrolled patients were divided into four groups according to baseline AF burden. RRAB and RRMD were monitored using CIEDs. Results: Overall, 145 eligible subjects received a naive AAD for nonpermanent AF. The mean RRAB in the four groups (AF burden <1%, 1%‐4%, 4%‐18%, and ≥18%) were −65.3%, −46.4%, −34.7%, and −27.9% (P = 0.005), respectively. Mean RRMD were −26.8%, −12.4%, 4.2%, and 6.0%, respectively (P = 0.006). Multivariate analysis revealed that the lowest baseline AF burden (<1%) was significantly associated with greater RRAB, which was not observed in the RRMD model. Conclusions: Lower baseline AF burden was associated with greater RRAB by AADs. Our finding suggests that rhythm control should be started in the early stage to achieve better responses to AADs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. TCTAP A-080 Effectiveness of Renal Denervation in Patients with Kidney-related Secondary Causes of Hypertension.
- Author
-
Lin, Shu-I., Lin, Po-Lin, Liu, Lawrence Yu-min, Chao, Chuan Lei, Chiou, Wei-Ru, Liao, Feng-Ching, and Lee, Ying-Hsiang
- Subjects
- *
DENERVATION , *HYPERTENSION , *ESSENTIAL hypertension , *ALDOSTERONE antagonists , *BLOOD pressure - Published
- 2019
- Full Text
- View/download PDF
16. Risk stratification of heart failure from one drop of blood using hand-held biosensor for BNP detection.
- Author
-
Sarangadharan, Indu, Wang, Shin-Li, Tai, Tse-Yu, Pulikkathodi, Anil Kumar, Hsu, Chen-Pin, Chiang, Hui-Hua Kenny, Liu, Lawrence Yu-Min, and Wang, Yu-Lin
- Subjects
- *
CARDIOVASCULAR diseases , *BIOSENSORS , *BRAIN natriuretic factor , *FIELD-effect transistors , *BLOOD cells - Abstract
Continued risk assessment by evaluating cardiac biomarkers in healthy and unhealthy individuals can lower the mortality rate of cardiovascular diseases (CVDs). In this research, we have developed a hand-held biosensor system to rapidly screen for brain natriuretic peptide (BNP) from a single drop of whole blood. The sensor methodology is based on extended gate design of electrical double layer (EDL) field effect transistor (FET), that can directly detect BNP in whole blood, without extensive sample pre-treatments, thereby eliminating the limitations of charge screening in high ionic strength solutions. A simple sensor array chip is fabricated to integrate with the MOSFET sensor system. Sensing characteristics are elucidated using purified BNP samples in 1 × PBS (with 4% BSA), spiked BNP samples in whole blood and clinical whole blood samples. The blood cells can be gravitationally separated without the use of any external actuation. The sensor exhibits very high sensitivity over wide dynamic range of detection. The sensing characteristics are not adversely affected by the presence of background proteins or blood cells, even without gravitational blood cell separation. Thus, the biosensor system can allow users to perform rapid whole blood diagnostics with minimal user protocols, in 5 min. The features of high sensitivity, cost-effectiveness and convenience of usage empower this technology to revolutionize the mobile diagnostics and healthcare industry. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Author Correction: Rhythm control without catheter ablation may have benefits beyond stroke prevention in rivaroxaban-treated non-permanent atrial fibrillation.
- Author
-
Chiou, Wei-Ru, Lin, Po-Lin, Huang, Chun-Che, Chuang, Jen-Yu, Liu, Lawrence Yu-Min, Su, Min-I, Liao, Feng-Ching, Kuo, Jen-Yuan, Tsai, Cheng-Ting, Wu, Yih-Jer, Wang, Kuang-Te, and Lee, Ying-Hsiang
- Subjects
- *
ATRIAL fibrillation , *CATHETER ablation - Abstract
Correction to: I Scientific Reports i https://doi.org/10.1038/s41598-022-07466-z, published online 08 March 2022 The original version of this Article contained an error in Affiliation 2, which was incorrectly given as 'Department of Medicine, Cardiovascular Center, MacKay Memorial Hospital, New Taipei, Taiwan'. The correct affiliation is listed below: Department of Medicine, MacKay Medical College, New Taipei, Taiwan. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
18. Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis.
- Author
-
Lien, Chi-Hone, Lee, Ming-Dar, Weng, Shun-Long, Lin, Chao-Hsu, Liu, Lawrence Yu-Min, Tai, Yu-Lin, Lei, Wei-Te, Liu, Jui-Ming, Huang, Ya-Ning, Chi, Hsin, Chiu, Nan-Chang, and Lin, Chien-Yu
- Subjects
- *
COVID-19 , *COLCHICINE , *SARS-CoV-2 , *RANDOMIZED controlled trials , *ARTIFICIAL respiration , *ODDS ratio - Abstract
Coronavirus disease 2019 (COVID-19) had caused huge health losses worldwide. Several drugs had been applied to treat patients with COVID-19, and repurposing colchicine had been proposed for its anti-inflammatory properties via several pathways. In this systematic review, we evaluated the effects of colchicine treatment. From inception to May 31, 2021, databases, including PubMed, EMbase, medRxiv, and Research Square were searched, and 11 studies were enrolled. A total of 17,205 COVID-19 patients with male predominance (62.9%) were analyzed. Patients with colchicine treatment had a significantly lower risk of mortality (odds ratio (OR): 0.57, 95% confidence interval (CI): 0.38–0.87, I2: 72%; p < 0.01) and a non-significantly lower rate of mechanical ventilation (OR: 0.67, 95%CI: 0.39–1.15). The side effects were mild and not significantly different (OR: 2.03, 95%CI: 0.51–8.09). Subgroup analysis with randomized controlled trials showed no statistically significant difference in the mortality (OR: 0.80, 95%CI: 0.44–1.46, I2: 33%; p = 0.22). In conclusion, our meta-analysis found that colchicine treatment was associated with a significantly lower risk of mortality in patients with COVID-19. However, this benefit was not observed in the subgroup analysis of randomized controlled trials. Further randomized controlled studies are required to confirm the potential benefits of colchicine treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Development of a rapid and economic in vivoelectrocardiogram platform for cardiovascular drug assay and electrophysiology research in adult zebrafish.
- Author
-
Lin, Min-Hsuan, Chou, Huang-Cheng, Chen, Yu-Fu, Liu, Wangta, Lee, Chi-Chun, Liu, Lawrence Yu-Min, and Chuang, Yung-Jen
- Abstract
Zebrafish is a popular and favorable model organism for cardiovascular research, with an increasing number of studies implementing functional assays in the adult stage. For example, the application of electrocardiography (ECG) in adult zebrafish has emerged as an important tool for cardiac pathophysiology, toxicity, and chemical screen studies. However, few laboratories are able to perform such functional analyses due to the high cost and limited availability of a convenient in vivo ECG recording system. In this study, an inexpensive ECG recording platform and operation protocol that has been optimized for adult zebrafish ECG research was developed. The core hardware includes integration of a ready-to-use portable ECG kit with a set of custom-made needle electrode probes. A combined anesthetic formula of MS-222 and isoflurane was first tested to determine the optimal assay conditions to minimize the interference to zebrafish cardiac physiology under sedation. For demonstration, we treated wild-type zebrafish with different pharmacological agents known to affect cardiac rhythms in humans. Conserved electrophysiological responses to these drugs were induced in adult zebrafish and recorded in real time. This economic ECG platform has the potential to facilitate teaching and training in cardiac electrophysiology with adult zebrafish and to promote future translational applications in cardiovascular medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.